ReviewFrontiers in pharmacology2026
Emerging links between TLR4 signaling and ferroptosis in heart failure.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron is an essential nutrient for living organisms, and the maintenance of its homeostatic balance within the body is a critical factor in ensuring normal physiological functions. Cardiomyocyte ferroptosis has emerged as a potential contributor to heart failure progression, involving complex regulatory mechanisms that remain incompletely understood. While the TLR4 signaling pathway was traditionally regarded as a therapeutic target for chronic inflammatory conditions, emerging evidence indicates that its activation may contribute to ferroptosis in cardiomyocytes. The proposed mechanisms through which TLR4 signaling may regulate cardiomyocyte ferroptosis are systematically summarized, and several therapeutic strategies targeting TLR4-associated ferroptosis are evaluated. Furthermore, promising avenues for future investigation are discussed, with particular emphasis on the need for direct mechanistic validation in cardiomyocytes and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.